Details

Autor(en) / Beteiligte

• Zboril, Emily K
• Grible, Jacqueline M
• Boyd, David C
• Hairr, Nicole S
• Leftwich, Tess J
• Esquivel, Madelyn F
• Duong, Alex K
• Turner, Scott A
• Ferreira-Gonzalez, Andrea
• Olex, Amy L
• Sartorius, Carol A
• Dozmorov, Mikhail G
• Harrell, J Chuck

Titel

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer

Ist Teil von

• Cancers, 2023-06, Vol.15 (12), p.3179

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Breast cancer alone accounts for the majority of cancer deaths among women, with the most commonly diagnosed subtype being estrogen receptor positive (ER+). Survival has greatly improved for patients with ER+ breast cancer, due in part to the development of antiestrogen compounds, such as tamoxifen. While treatment of the primary disease is often successful, as many as 30% of patients will experience recurrence and metastasis, mainly due to developed endocrine therapy resistance. In this study, we discovered two tamoxifen combination therapies, with simeprevir and VX-680, that reduce the tumor burden in animal models of ER+ breast cancer more than either compound or tamoxifen alone. Additionally, these tamoxifen combinations reduced the expression of HER2, a hallmark of tamoxifen treatment, which can facilitate acquisition of a treatment-resistant phenotype. These combinations could provide clinical benefit by potentiating tamoxifen treatment in ER+ breast cancer.